Skip to content

Borrelia Species in Cutaneous Lyme Borreliosis

DIVERSITY OF BORRELIA SPECIES INVOLVED IN CUTANEOUS MANIFESTATIONS OF LYME BORRELIOSIS IN FRANCE

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00576082
Enrollment
900
Registered
2007-12-18
Start date
2008-03-31
Completion date
2022-12-31
Last updated
2022-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lyme Borreliosis

Keywords

Lyme borreliosis, Erythema migrans, Borrelial lymphocytoma, Acrodermatitis chronica atrophicans, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii

Brief summary

The aim of this study is to identify the species of Borrelia involved in the dermatologic manifestations of Lyme borreliosis in France. Indeed, in Europe, as opposed to North America, many bacterial species are involved in Lyme borreliosis. Yet, very few is known about the prevalence and distribution of different bacteriological species that account for the disease in France. Thus, this a nation-wide study in which all French dermatologists are invited to participate. Every adult patient presenting with one of the cutaneous manifestation of Lyme borreliosis: erythema migrans, lymphocytoma or acrodermatitis chronica atrophicans can be included in the study. If the patient agrees participating, after information and written consent, a cutaneous biopsy will be performed in order to isolate Borrelia by means of culture and PCR. An estimated 400 biopsies should be performed within 2 years.

Interventions

Cutaneous biopsy in order to search Borrelia by means of culture and PCR in this tissue sample

Sponsors

Société de Dermatologie Française
CollaboratorOTHER
University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed adult patient who signed written consent with one the following conditions: * erythema migrans * borrelial lymphocytoma * acrodermatitis chronica atrophicans

Exclusion criteria

* pregnancy or lactation * allergy to local anesthesia * patient who refuses biopsy

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026